Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122804 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL31616404 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL563252 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL30724855 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL2552181 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18237339 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18089434 | 1.00 | TSHR (0.40) | TSHR | |
| Hydrochloric Acid SCHEMBL25375836 | 0.97 | TSHR (0.39) | TSHR | |
| SCHEMBL2818899 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL25377147 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025120219-A2 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | disclosed |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12084517-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2024-09-10 | — | — | US | disclosed |
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | LYCIA THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240156972-A1 | ANTIBODY RECRUITMENT MOLECULES AND METHODS OF TREATING CANCER USING SAME | MCMASTER UNIVERSITY (CA) | 2024-05-16 | — | — | US | disclosed |
| EP-4359414-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | Lycia Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4298131-A1 | ANTIBODY RECRUITMENT MOLECULES AND METHODS OF TREATING CANCER USING SAME | McMaster University (CA) | 2024-01-03 | — | — | EP | disclosed |
| EP-2991677-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | Yale University (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178878-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | YALE UNIVERSITY (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8859509-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859509-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8852630-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2012-02-09 | — | — | US | disclosed |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2291659-A2 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | Yale University, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009139863-A2 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | TSHR 4176/4885 |
| US-20240156972-A1 | ANTIBODY RECRUITMENT MOLECULES AND METHODS OF TREATING CANCER USING SAME | HAVCR2, CD40LG, CD81 | TSHR 3500/4885 |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | FOLR1, FOLR2, FOLH1 | TSHR 137/4885 |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | TSHR 4176/4885 |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | FOLR1, FOLR2, FOLH1 | TSHR 137/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | TSHR 4176/4885 |
| US-12084517-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | TSHR 4176/4885 |
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | TSHR 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.